HALO Peter Lynch Fair Value
Peter Lynch Fair Value Assumptions
Peter Lynch Fair Value Calculation
Fair Value
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
HALO EPS growth & Dividend Yield
HALO vs Peer Set: Peter Lynch Fair Value Comparison
General
PETER LYNCH FAIR VALUE
Financial metrics
Company name
Undervaluation / Overvaluation
Revenue growth
EBITDA margin
Net Income margin
Explore more intrinsic value tools hub for HALO
FAQ
What is Halozyme Therapeutics, Inc. fair value by Peter Lynch formula?
As of Mar 11, 2025, Halozyme Therapeutics, Inc.'s fair value using the Peter Lynch formula is $135.7 per share. The current price of $61.4 suggests Halozyme Therapeutics, Inc. may be undervalued by this metric.
What is Halozyme Therapeutics, Inc. Price to Earnings (P/E) ratio?
As of Mar 11, 2025, Halozyme Therapeutics, Inc.'s P/E ratio is 17.5x. This is calculated by dividing the current share price of $61.4 by the Earnings per Share (EPS) for the trailing twelve months, which is $3.5. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
What is Halozyme Therapeutics, Inc. earnings per share (EPS)?
Halozyme Therapeutics, Inc. earnings per share (EPS) for the twelve months ending Mar 11, 2025, was $3.5, a 38.7% growth year-over-year.